Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1517-1520

  Liew, Elena ^a   Atenafu, Eshetu G ^a   Schimmer, Aaron D ^a   Yee, Karen W L ^a   Schuh, Andre C ^a   Minden, Mark D ^a   Gupta, Vikas ^a   Brandwein, Joseph M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute; Allogeneic stem cell transplantation; Chemotherapy; Leukemia; Lymphoblastic

Indexed keywords

ANTILEUKEMIC AGENT; DASATINIB; NILOTINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84868206208     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.019     Document Type: Article

References (24)

1. Gokbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46(1):64-75.
2. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354(2):166-178.
3. Thomas D.A., Kantarjian H., Smith T.L., Koller C., Cortes J., O'Brien S., et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999, 86(7):1216-1230.
4. Fielding A.K., Richards S.M., Chopra R., Lazarus H.M., Litzow M.R., Buck G., et al. Medical Research Council of the United Kingdom Adult ALL Working Party. Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109(3):944-950.
5. Tavernier E., Boiron J.M., Huguet F., Bradstock K., Vey N., Kovacsovics T., et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007, 21(9):1907-1914.
6. Oriol A., Vives S., Hernandez-Rivas J.M., Tormo M., Heras I., Rivas C., et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010, 95(4):589-596.
7. Kantarjian H.M., Thomas D., Ravandi F., Faderl S., Garcia-Manero G., Shan J., et al. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 2010, 51(3):475-480.
8. Welborn J.L. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 1994, 45(4):341-344.
9. Ram R., Wolach O., Vidal L., Gafter-Gvili A., Shpilberg O., Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012, 87(5):472-478.
10. Storring J.M., Minden M.D., Kao S., Gupta V., Schuh A.C., Schimmer A.D., et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 2009, 146(1):76-85.
11. Thyagu S., Minden M.D., Gupta V., Yee K.W., Schimmer A.D., Schuh A.C., et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. Br J Haematol 2012, 158:506-514.
12. Gupta V., Yi Q.L., Brandwein J., Minden M.D., Schuh A.C., Wells R.A., et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004, 33(4):397-404.
13. Koller C.A., Kantarjian H.M., Thomas D., O'Brien S., Rios M.B., Kornblau S., et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997, 11(12):2039-2044.
14. Advani A., Jin T., Bolwell B., Copelan E., Sekeres M., Sobecks R., et al. A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse. Leuk Lymphoma 2009, 50(7):1126-1131.
15. Kozlowski P., Astrom M., Ahlberg L., Bernell P., Hulegardh E., Hagglund H., et al. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. Haematologica 2012, 97. 10.3324/haematol.2011.057851.
16. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23(5):1083-1098. vii.
17. Bruggemann M., Raff T., Flohr T., Gokbuget N., Nakao M., Droese J., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107(3):1116-1123.
18. Raff T., Gokbuget N., Luschen S., Reutzel R., Ritgen M., Irmer S., et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109(3):910-915.
19. Bassan R., Spinelli O., Oldani E., Intermesoli T., Tosi M., Peruta B., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113(18):4153-4162.
20. Holowiecki J., Krawczyk-Kulis M., Giebel S., Jagoda K., Stella-Holowiecka B., Piatkowska-Jakubas B., et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008, 142(2):227-237.
21. Hoelzer D., Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012, 26(1):25-32.
22. Topp M.S., Kufer P., Gokbuget N., Goebeler M., Klinger M., Neumann S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29(18):2493-2498.
23. Topp M.S., Goekbuget N., Zugmaier G., Viardot A., Stelljes M., Neumann S., et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Blood 2011, 118(21):252a.
24. Kantarjian H., Thomas D., Jorgensen J., Jabbour E., Kebriaei P., Rytting M., et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012, 13(4):311-403.